IMVT Quote, Financials, Valuation and Earnings

Nutriband, Inc. has a net margin of -- compared to Immunovant, Inc.'s net margin of -1118.87%. Immunovant, Inc.'s return on equity of -73.12% beat Nutriband, Inc.'s return on equity of -164.64%.

Immunovant, Inc. has a consensus price target of $40.59, signalling upside risk potential of 63.99%. On the other hand Nutriband, Inc. has an analysts' consensus of $15.00 which suggests that it could grow by 313.22%. Given that Nutriband, Inc. has higher upside potential than Immunovant, Inc., analysts believe Nutriband, Inc. is more attractive than Immunovant, Inc..

Immunovant, Inc. has a beta of 0.673, which suggesting that the stock is 32.666% less volatile than S&P 500. In comparison Nutriband, Inc. has a beta of 1.948, suggesting its more volatile than the S&P 500 by 94.828%.

Immunovant, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nutriband, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immunovant, Inc. pays -- of its earnings as a dividend. Nutriband, Inc. pays out -- of its earnings as a dividend.

Immunovant, Inc. quarterly revenues are --, which are smaller than Nutriband, Inc. quarterly revenues of $346.1K. Immunovant, Inc.'s net income of -$110.6M is lower than Nutriband, Inc.'s net income of -$3.9M. Notably, Immunovant, Inc.'s price-to-earnings ratio is -- while Nutriband, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immunovant, Inc. is -- versus 19.07x for Nutriband, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics, Inc. has a net margin of -- compared to Immunovant, Inc.'s net margin of -417.92%. Immunovant, Inc.'s return on equity of -73.12% beat Plus Therapeutics, Inc.'s return on equity of --.

Immunovant, Inc. has a consensus price target of $40.59, signalling upside risk potential of 63.99%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $146.88 which suggests that it could grow by 4025.7%. Given that Plus Therapeutics, Inc. has higher upside potential than Immunovant, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Immunovant, Inc..

Immunovant, Inc. has a beta of 0.673, which suggesting that the stock is 32.666% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 1.025, suggesting its more volatile than the S&P 500 by 2.509%.

Immunovant, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immunovant, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Immunovant, Inc. quarterly revenues are --, which are smaller than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Immunovant, Inc.'s net income of -$110.6M is lower than Plus Therapeutics, Inc.'s net income of -$5.7M. Notably, Immunovant, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immunovant, Inc. is -- versus 3.21x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Viridian Therapeutics, Inc. has a net margin of -- compared to Immunovant, Inc.'s net margin of -77256.06%. Immunovant, Inc.'s return on equity of -73.12% beat Viridian Therapeutics, Inc.'s return on equity of -53.74%.

Immunovant, Inc. has a consensus price target of $40.59, signalling upside risk potential of 63.99%. On the other hand Viridian Therapeutics, Inc. has an analysts' consensus of $37.24 which suggests that it could grow by 97.64%. Given that Viridian Therapeutics, Inc. has higher upside potential than Immunovant, Inc., analysts believe Viridian Therapeutics, Inc. is more attractive than Immunovant, Inc..

Immunovant, Inc. has a beta of 0.673, which suggesting that the stock is 32.666% less volatile than S&P 500. In comparison Viridian Therapeutics, Inc. has a beta of 1.166, suggesting its more volatile than the S&P 500 by 16.64%.

Immunovant, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viridian Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immunovant, Inc. pays -- of its earnings as a dividend. Viridian Therapeutics, Inc. pays out -- of its earnings as a dividend.

Immunovant, Inc. quarterly revenues are --, which are smaller than Viridian Therapeutics, Inc. quarterly revenues of $132K. Immunovant, Inc.'s net income of -$110.6M is lower than Viridian Therapeutics, Inc.'s net income of -$102M. Notably, Immunovant, Inc.'s price-to-earnings ratio is -- while Viridian Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immunovant, Inc. is -- versus 22.15x for Viridian Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.